×
Peak Bio Price to Free Cash Flow Ratio 2021-2024 | PKBO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Peak Bio price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
View More
Peak Bio Price to Free Cash Flow Ratio 2021-2024 | PKBO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Peak Bio price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$180.5B
Regeneron Pharmaceuticals (REGN)
$126.8B
Vertex Pharmaceuticals (VRTX)
$123.3B
Gilead Sciences (GILD)
$104.5B
Bristol Myers Squibb (BMY)
$99.4B
CSL (CSLLY)
$97.5B
GSK (GSK)
$86.3B
Alnylam Pharmaceuticals (ALNY)
$35.5B
Argenex SE (ARGX)
$32.1B
Biogen (BIIB)
$29.3B
BioNTech SE (BNTX)
$26.8B
Moderna (MRNA)
$26.1B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$19.3B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.6B
Exact Sciences (EXAS)
$13.1B
Vaxcyte (PCVX)
$13.1B
Insmed (INSM)
$12.9B
Incyte (INCY)
$12.9B
Bio-Techne Corp (TECH)
$12.7B
Sarepta Therapeutics (SRPT)
$12.1B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Ascendis Pharma (ASND)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Exelixis (EXEL)
$7.7B